HUMANIGEN INC
HUMANIGEN INC
Acción · US4448632038 · HGEN · A2QEQW (XNAS)
Resumen Indicadores financieros
Sin cotización
n/a

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
- - - - 0,00 % 0,00 % -100,00 %

Perfil de la empresa para HUMANIGEN INC Acción

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Datos de la empresa

Nombre HUMANIGEN INC
Empresa Humanigen, Inc.
Símbolo HGEN
Sitio web https://www.humanigen.com
Mercado principal XNAS NASDAQ
WKN A2QEQW
ISIN US4448632038
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Cameron Durrant M.D., MBA
País Estados Unidos de América
Moneda USD
Empleados 0,0 T
Dirección 830 Morris Turnpike, 07078-2625 Short Hills
Fecha de OPV 2013-01-31

Splits de acciones

Fecha Split
14.09.2020 1:5
14.07.2015 1:8

Cambios de identificador

Fecha De A
11.08.2017 KBIO HGEN

Símbolos de cotización

Nombre Símbolo
NASDAQ HGEN

Otras acciones

Los inversores que tienen HUMANIGEN INC también tienen las siguientes acciones en su cartera:
ACTIVISION BLIZZARD INC
ACTIVISION BLIZZARD INC Acción
ADTRAN HOLDINGS INC
ADTRAN HOLDINGS INC Acción
AMGEN INC
AMGEN INC Acción
AUTODESK INC
AUTODESK INC Acción
BROADCO INC
BROADCO INC Acción
CISCO SYSTEMS INC
CISCO SYSTEMS INC Acción
CONDUENT INC
CONDUENT INC Acción
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Acción
DWS NOMUR.JAP.GROWTH LCHP
DWS NOMUR.JAP.GROWTH LCHP Fondo
INTEL CORP
INTEL CORP Acción
MICROSOFT CORP
MICROSOFT CORP Acción
Smead Value Fund Class Y
Smead Value Fund Class Y Fondo
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Acción
XCEL ENERGY 21/27
XCEL ENERGY 21/27 Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025